Group 1 - The Huatai-PineBridge STAR Market Innovative Drug ETF (589123) will be available for subscription from August 25, 2025, to September 5, 2025 [1] - The fund is managed by Huatai-PineBridge Fund Management, with Luo Hao serving as the fund manager [1] - The performance benchmark for the fund is the Shanghai Stock Exchange STAR Market Innovative Drug Index return [1]

Group 1 - The core index of the Shanghai Stock Exchange Science and Technology Innovation Board for innovative drugs remained flat, closing at 0.0 points with a trading volume of 0.0 billion yuan [1] - The index has shown a monthly increase of 0.15%, a three-month increase of 15.81%, and a year-to-date increase of 24.30% [1] - The index is composed of no more than 30 listed companies in the innovative drug sector, reflecting the overall performance of these companies on the Science and Technology Innovation Board [1] Group 2 - The top ten weighted companies in the index include: Bai Li Tianheng (10.7%), BeiGene (10.04%), Aier Pharmaceutical (9.31%), Zai Lab (8.4%), Junshi Biosciences (7.59%), Teruisi Biopharma (5.83%), Rongchang Biopharma (4.39%), Dize Pharmaceutical (3.81%), Nuotai Biopharma (3.52%), and Yifang Biopharma (3.45%) [1] - The index's holdings are entirely from the Shanghai Stock Exchange, with a sector breakdown of 49.12% in other biopharmaceuticals, 35.60% in pharmaceutical preparations, 11.83% in pharmaceutical and biotechnology services, and 3.46% in vaccines [1]